| Symbol | CADL |
|---|---|
| Name | CANDEL THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 117 KENDRICK STREET,SUITE 450, NEEDHAM, Massachusetts, 02494, United States |
| Telephone | +1 617 916-5445 |
| Fax | — |
| — | |
| Website | https://www.candeltx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001841387 |
| Description | Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies. Additional info from NASDAQ: |
2026-09-11 22:12
Tak Paul Peter 🟡 adjusted position in 280.2K shares (1 derivative) of Candel Therapeutics, Inc. (CADL) at $11.50 ($3.5M) Transaction Date: Sep 10, 2026 | Filing ID: 000002
Read more
2026-09-10 20:39
📋 PAUL PETER TAK (Director) plans to sell 280K shares of CANDEL THERAPEUTICS, INC. (at $12.17 each, total $3.4M) Filed: Sep 10, 2026 | ID: 009295
Read more
2026-09-10 20:24
Zimmermann Martine 🟢 acquired 64.0K shares (1 derivative) of Candel Therapeutics, Inc. (CADL) at $12.60 Transaction Date: Sep 08, 2026 | Filing ID: 387924
Read more
2026-09-10 17:22
New Form 3 - Candel Therapeutics, Inc. <b>Filed:</b> 2026-09-10 <b>AccNo:</b> 0001193125-26-387919 <b>Size:</b> 15 KB
Read more
2026-09-10 12:16
(85% Positive) CANDEL THERAPEUTICS, INC. (CADL) Provides Update on outcomes for our evolution
Read more
2026-09-10 12:05
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
Read more
2026-09-01 20:05
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-08-17 20:37
📋 SESHU TYAGARAJAN (Officer) plans to sell 7K shares of CANDEL THERAPEUTICS, INC. (at $11.72 each, total $82K) Filed: Aug 17, 2026 | ID: 008263
Read more
2026-08-13 12:15
(90% Positive) CANDEL THERAPEUTICS, INC. (CADL) Announces Enrollment Update for enrollment Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV … | Phase3 | Non-squamous, Non-Small Cell Lung Cancer | Recruiting | 2026-06-15 | 2031-10-22 | ClinicalTrials.gov |
| NCT07332000 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimage… | Phase2 | Prostate Cancer Patients Treated by Radiotherapy | Recruiting | 2025-10-30 | 2026-08-01 | ClinicalTrials.gov |
| NCT07385443 | The Spanish National Registry for Myotonic Dystrophy Type 1 | — | Myotonic Dystrophy 1 | Recruiting | 2025-06-02 | 2026-12-31 | ClinicalTrials.gov |
| NCT06327672 | INOCA Spanish National Registry | — | Non-Obstructive Coronary Atherosclerosis | Unknown | 2024-03-24 | 2026-03-01 | ClinicalTrials.gov |
| NCT06219278 | A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wr… | — | Wrinkle | Completed | 2023-10-29 | 2024-07-01 | ClinicalTrials.gov |
| NCT06202274 | Clinical Study to Evaluate the Safety and Efficacy of Candela Technology | Na | Hair Reduction | Active_Not_Recruiting | 2023-10-04 | 2029-10-04 | ClinicalTrials.gov |
| NCT06108271 | Innovative Endotracheal Tube Design Reduces Postoperative Laryngeal Injury | Na | Laryngeal Injury | Unknown | 2023-10-01 | 2023-11-15 | ClinicalTrials.gov |
| NCT06064071 | Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD | Na | Meibomian Gland Dysfunction | Active_Not_Recruiting | 2023-09-18 | 2025-09-01 | ClinicalTrials.gov |
| NCT04898491 | Validity and Reliability Study of the Pain Indicator Behavior Scale-Brain Damag… | — | Pain | Recruiting | 2022-06-01 | 2025-06-30 | ClinicalTrials.gov |
| NCT06031766 | Comparison of CIPA With the GLIM Criteria and Prevalence of Sarcopenia in Inpat… | — | Malnutrition | Unknown | 2022-01-07 | 2024-06-30 | ClinicalTrials.gov |
| NCT04975243 | Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro™/GentleM… | Na | Unwanted Fine Facial Hair | Unknown | 2021-03-19 | 2023-09-30 | ClinicalTrials.gov |
| NCT04993066 | Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus | Na | Pseudofolliculitis Barbae | Completed | 2020-11-12 | 2023-04-27 | ClinicalTrials.gov |
| NCT06192550 | Functional Usability and Feasibility Testing of the Profound Matrix™ System | Na | Wrinkle | Completed | 2020-10-28 | 2023-12-29 | ClinicalTrials.gov |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Sta… | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2020-10-13 | 2026-12-01 | ClinicalTrials.gov |
| NCT04463706 | COVID19 Severity Prediction and Health Services Research Evaluation | — | Covid19 | Completed | 2020-06-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT04245696 | Bipolar RF Microneedling for Improved Laxity and Lift of the Submental and Neck… | Na | Skin Laxity | Withdrawn | 2020-03-09 | 2021-08-05 | ClinicalTrials.gov |
| NCT04202419 | Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions | Na | Pigmented Skin Lesion | Completed | 2020-01-09 | 2021-04-26 | ClinicalTrials.gov |
| NCT04203745 | Nonablative Fractional Diode Laser for Treatment of Skin Resurfacing and Pigmen… | Na | Skin Texture | Completed | 2019-09-18 | 2021-08-05 | ClinicalTrials.gov |
| NCT03949140 | Laser Hair Removal for Treatment of Pilonidal Disease | Na | Pilonidal Disease | Completed | 2019-02-18 | 2021-10-30 | ClinicalTrials.gov |
| NCT03774849 | PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles | Na | Benign Pigmented Lesions | Completed | 2018-12-05 | 2020-11-12 | ClinicalTrials.gov |
| NCT04148651 | The CO2RE® System for Vulvar Lichen Sclerosus | Na | Vulvar Lichen Sclerosus | Completed | 2018-07-11 | 2020-12-17 | ClinicalTrials.gov |
| NCT03257670 | Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in… | Na | Dyspareunia | Unknown | 2018-03-20 | 2022-06-01 | ClinicalTrials.gov |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnose… | Phase1 | Glioma, Malignant | Completed | 2018-02-27 | 2023-06-30 | ClinicalTrials.gov |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Phase1 | Malignant Glioma of Brain | Active_Not_Recruiting | 2017-07-18 | 2028-01-01 | ClinicalTrials.gov |
| NCT02776046 | Individualized Perioperative Open-lung Ventilatory Strategy With High Versus Co… | Na | Hyperoxia | Unknown | 2017-06-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT03131037 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable … | Phase1 | Lung Cancer | Completed | 2017-05-04 | 2023-09-20 | ClinicalTrials.gov |
| NCT02956720 | UltraShape Power in Combination With U-sculpt-n Transducer | Na | Circumference Reduction | Unknown | 2017-01-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillanc… | Phase2 | Prostate Cancer | Active_Not_Recruiting | 2016-05-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02446093 | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline … | Phase2 | Borderline Resectable Pancreatic Adenocarcinoma | Active_Not_Recruiting | 2015-10-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT02352220 | Determinants of Onset and Progression of COPD in Young Adults | — | COPD | Unknown | 2015-01-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | Phase1 | Malignant Pleural Effusion | Completed | 2013-10-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02105753 | Tx Axillary Hyperhidrosis 1210nm Diode Laser | Na | Axillary Hyperhidrosis | Unknown | 2013-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01775722 | Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment | Na | Port-Wine Stain | Completed | 2012-12-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for L… | Phase3 | Prostate Cancer | Active_Not_Recruiting | 2011-09-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT01577368 | Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas… | Phase3 | Pseudomonas Aeruginosa Infection | Completed | 2011-05-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01299922 | Clinical Trial Treatment in Lupus Nephritis | Phase3 | Lupus Nephritis | Withdrawn | 2011-02-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01217151 | Perioperative Hemodynamic Optimization Using the NICOM Device | Na | Major Abdominal Surgery | Completed | 2011-01-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Thera… | Phase1 | Malignant Glioma | Completed | 2010-10-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | Phase1 | Pancreatic Adenocarcinoma | Completed | 2008-08-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01574547 | Risk Factors of Cat Scratch Colon Developing. | — | Mucosal Erosion | Completed | 2007-09-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | Phase2 | Malignant Glioma | Completed | 2007-03-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00585715 | Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening | Na | Localized Lipodystrophy | Completed | 2006-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Mal… | Phase1 | Malignant Glioma | Completed | 2005-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00306371 | Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1… | — | Acne | Completed | 2004-07-01 | 2006-02-01 | ClinicalTrials.gov |
Total clinical trials: 44
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Docetaxel | Other | Phase PHASE3 | Non-squamous, Non-Small Cell Lung Cancer | RECRUITING | NCT07660094 |
| Pembrolizumab | Other | Phase PHASE3 | Non-squamous, Non-Small Cell Lung Cancer | RECRUITING | NCT07660094 |
| Valacyclovir | Other | Phase PHASE3 | Non-squamous, Non-Small Cell Lung Cancer | RECRUITING | NCT07660094 |
| Aglatimagene Besadenovec | Other | Phase PHASE3 | Non-squamous, Non-Small Cell Lung Cancer | RECRUITING | NCT07660094 |
| 1450nm diode laser | Other | Preclinical | Acne | COMPLETED | NCT00306371 |
| Mycophenolic Acid + prednison | Other | Phase PHASE3 | Lupus Nephritis | WITHDRAWN | NCT01299922 |
| cyclosporine +mycophenolic acid+prednison | Other | Phase PHASE3 | Lupus Nephritis | WITHDRAWN | NCT01299922 |
| Predictors of health care provide | Other | Preclinical | Covid19 | COMPLETED | NCT04463706 |
| Predictors adverse evolution | Other | Preclinical | Covid19 | COMPLETED | NCT04463706 |
| CAN-2409 + valacyclovir | Other | Phase PHASE1 | Lung Cancer | COMPLETED | NCT03131037 |
| 1450nm diode laser | Other | Preclinical | Acne | COMPLETED | NCT00306371 |
| 1450nm diode laser | Other | Preclinical | Acne | COMPLETED | NCT00306371 |
| Usual treatment | Drug | Approved | Major Abdominal Surgery | COMPLETED | NCT01217151 |
| Hemodynamic monitoring | Other | Approved | Major Abdominal Surgery | COMPLETED | NCT01217151 |
| Usual treatment | Drug | Approved | Major Abdominal Surgery | COMPLETED | NCT01217151 |
| Hemodynamic monitoring | Other | Approved | Major Abdominal Surgery | COMPLETED | NCT01217151 |
| Piperacillin-Tazobactam intermittent infusion | Other | Phase PHASE3 | Pseudomonas Aeruginosa Infection | COMPLETED | NCT01577368 |
| Piperacillin-Tazobactam continuous infusion | Other | Phase PHASE3 | Pseudomonas Aeruginosa Infection | COMPLETED | NCT01577368 |
| Piperacillin-Tazobactam intermittent infusion | Other | Phase PHASE3 | Pseudomonas Aeruginosa Infection | COMPLETED | NCT01577368 |
| Piperacillin-Tazobactam continuous infusion | Other | Phase PHASE3 | Pseudomonas Aeruginosa Infection | COMPLETED | NCT01577368 |
| 1210nm Diode Laser treatments | Drug | Approved | Axillary Hyperhidrosis | UNKNOWN | NCT02105753 |
| 1210nm Diode Laser treatments | Drug | Approved | Axillary Hyperhidrosis | UNKNOWN | NCT02105753 |
| Mycophenolic Acid + prednison | Other | Phase PHASE3 | Lupus Nephritis | WITHDRAWN | NCT01299922 |
| cyclosporine +mycophenolic acid+prednison | Other | Phase PHASE3 | Lupus Nephritis | WITHDRAWN | NCT01299922 |
| UltraShape Power | Other | Approved | Circumference Reduction | UNKNOWN | NCT02956720 |
| UltraShape Power | Other | Approved | Circumference Reduction | UNKNOWN | NCT02956720 |
| Conventional FiO2 | Other | Approved | Hyperoxia | UNKNOWN | NCT02776046 |
| High FiO2 | Other | Approved | Hyperoxia | UNKNOWN | NCT02776046 |
| Conventional FiO2 | Other | Approved | Hyperoxia | UNKNOWN | NCT02776046 |
| High FiO2 | Other | Approved | Hyperoxia | UNKNOWN | NCT02776046 |
| Dermal Handpiece / SubQ Handpiece | Other | Approved | Skin Laxity | WITHDRAWN | NCT04245696 |
| Dermal Handpiece / SubQ Handpiece | Other | Approved | Skin Laxity | WITHDRAWN | NCT04245696 |
| CO2RE fractional laser therapy | Drug | Approved | Dyspareunia | UNKNOWN | NCT03257670 |
| 4% Topical Lidocaine Gel | Other | Approved | Dyspareunia | UNKNOWN | NCT03257670 |
| CO2RE fractional laser therapy | Drug | Approved | Dyspareunia | UNKNOWN | NCT03257670 |
| 4% Topical Lidocaine Gel | Other | Approved | Dyspareunia | UNKNOWN | NCT03257670 |
| Laser hair removal | Other | Approved | Pilonidal Disease | COMPLETED | NCT03949140 |
| Laser hair removal | Other | Approved | Pilonidal Disease | COMPLETED | NCT03949140 |
| The CO2RE® System | Other | Approved | Vulvar Lichen Sclerosus | COMPLETED | NCT04148651 |
| The CO2RE® System | Other | Approved | Vulvar Lichen Sclerosus | COMPLETED | NCT04148651 |
| 1064 nm Nd:YAG laser | Other | Approved | Localized Lipodystrophy | COMPLETED | NCT00585715 |
| 1064 nm Nd:YAG laser | Other | Approved | Localized Lipodystrophy | COMPLETED | NCT00585715 |
| Combined Bipolar Radiofrequency&Pulsed Dye Laser | Other | Approved | Port-Wine Stain | COMPLETED | NCT01775722 |
| Pulsed Dye Laser | Other | Approved | Port-Wine Stain | COMPLETED | NCT01775722 |
| Combined Bipolar Radiofrequency&Pulsed Dye Laser | Other | Approved | Port-Wine Stain | COMPLETED | NCT01775722 |
| Pulsed Dye Laser | Other | Approved | Port-Wine Stain | COMPLETED | NCT01775722 |
| GentleMax Pro Plus 755nm and 1064nm laser system | Other | Approved | Unwanted Fine Facial Hair | UNKNOWN | NCT04975243 |
| GentleMax Pro Plus 755nm and 1064nm laser system | Other | Approved | Unwanted Fine Facial Hair | UNKNOWN | NCT04975243 |
| Nonablative Fractional Diode Laser | Other | Approved | Skin Texture | COMPLETED | NCT04203745 |
| Nonablative Fractional Diode Laser | Other | Approved | Skin Texture | COMPLETED | NCT04203745 |
| FRAX 1940 nm laser | Other | Approved | Pigmented Skin Lesion | COMPLETED | NCT04202419 |
| FRAX 1940 nm laser | Other | Approved | Pigmented Skin Lesion | COMPLETED | NCT04202419 |
| AdV-tk + valacyclovir | Other | Phase PHASE1 | Malignant Pleural Effusion | COMPLETED | NCT01997190 |
| Dietary supplement | Other | Preclinical | Malnutrition | UNKNOWN | NCT06031766 |
| Dietary supplement | Other | Preclinical | Malnutrition | UNKNOWN | NCT06031766 |
| Dietary supplement | Other | Preclinical | Malnutrition | UNKNOWN | NCT06031766 |
| Conventional endotracheal tube | Other | Approved | Laryngeal Injury | UNKNOWN | NCT06108271 |
| Triglotix® | Other | Approved | Laryngeal Injury | UNKNOWN | NCT06108271 |
| Conventional endotracheal tube | Other | Approved | Laryngeal Injury | UNKNOWN | NCT06108271 |
| Triglotix® | Other | Approved | Laryngeal Injury | UNKNOWN | NCT06108271 |
| GentleMax Pro Plus | Other | Approved | Pseudofolliculitis Barbae | COMPLETED | NCT04993066 |
| GentleMax Pro Plus | Other | Approved | Pseudofolliculitis Barbae | COMPLETED | NCT04993066 |
| PicoWay™ 1064nm fractional handpiece | Other | Approved | Benign Pigmented Lesions | COMPLETED | NCT03774849 |
| PicoWay™ 730nm wavelength | Other | Approved | Benign Pigmented Lesions | COMPLETED | NCT03774849 |
| PicoWay™ 532nm fractional handpiece | Other | Approved | Benign Pigmented Lesions | COMPLETED | NCT03774849 |
| PicoWay™ 1064nm fractional handpiece | Other | Approved | Benign Pigmented Lesions | COMPLETED | NCT03774849 |
| PicoWay™ 730nm wavelength | Other | Approved | Benign Pigmented Lesions | COMPLETED | NCT03774849 |
| PicoWay™ 532nm fractional handpiece | Other | Approved | Benign Pigmented Lesions | COMPLETED | NCT03774849 |
| Surgery | Procedure | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Stereotactic body radiation therapy | Drug | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Chemoradiation | Other | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Aglatimagene besadenovec | Other | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Predictors of health care provide | Other | Preclinical | Covid19 | COMPLETED | NCT04463706 |
| Predictors adverse evolution | Other | Preclinical | Covid19 | COMPLETED | NCT04463706 |
| Profound Matrix | Other | Preclinical | Wrinkle | COMPLETED | NCT06219278 |
| Profound Matrix | Other | Preclinical | Wrinkle | COMPLETED | NCT06219278 |
| Profound Matrix™ System | Other | Approved | Wrinkle | COMPLETED | NCT06192550 |
| Profound Matrix™ System | Other | Approved | Wrinkle | COMPLETED | NCT06192550 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Nivolumab | Other | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Temozolomide | Other | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Radiation | Other | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Valacyclovir | Other | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| AdV-tk | Other | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Pain assessment using a behavioral scale | Other | Preclinical | Pain | RECRUITING | NCT04898491 |
| Pain assessment using a behavioral scale | Other | Preclinical | Pain | RECRUITING | NCT04898491 |
| Pain assessment using a behavioral scale | Other | Preclinical | Pain | RECRUITING | NCT04898491 |
| valacyclovir | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| placebo | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| aglatimagene besadenovec | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| Placebo + valacyclovir | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT01436968 |
| Aglatimagene besadenovec + valacyclovir | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT01436968 |
| Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE | Other | Approved | Hair Reduction | ACTIVE_NOT_RECRUITING | NCT06202274 |
| Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE | Other | Approved | Hair Reduction | ACTIVE_NOT_RECRUITING | NCT06202274 |
| Sham Nordlys SWT IPL | Other | Approved | Meibomian Gland Dysfunction | ACTIVE_NOT_RECRUITING | NCT06064071 |
| Meibomian Gland Expression (MGX) | Other | Approved | Meibomian Gland Dysfunction | ACTIVE_NOT_RECRUITING | NCT06064071 |
| Nordlys SWT IPL | Other | Approved | Meibomian Gland Dysfunction | ACTIVE_NOT_RECRUITING | NCT06064071 |
| Sham Nordlys SWT IPL | Other | Approved | Meibomian Gland Dysfunction | ACTIVE_NOT_RECRUITING | NCT06064071 |
| Meibomian Gland Expression (MGX) | Other | Approved | Meibomian Gland Dysfunction | ACTIVE_NOT_RECRUITING | NCT06064071 |
| Nordlys SWT IPL | Other | Approved | Meibomian Gland Dysfunction | ACTIVE_NOT_RECRUITING | NCT06064071 |
| Aglatimagene besadenovec | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04495153 |
| Patient Registry | Other | Preclinical | Myotonic Dystrophy 1 | RECRUITING | NCT07385443 |
| Patient Registry | Other | Preclinical | Myotonic Dystrophy 1 | RECRUITING | NCT07385443 |
| Stereotactic biopsy | Other | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| Cyclophosphamide | Other | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| rQNestin | Other | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | Prostate Cancer Patients Treated by Radiotherapy | RECRUITING | NCT07332000 |
| aglatimagene besadenovec + valacyclovir | Other | Phase PHASE2 | Prostate Cancer Patients Treated by Radiotherapy | RECRUITING | NCT07332000 |
| External Beam Radiation Therapy (EBRT) | RADIATION | Phase PHASE2 | Prostate Cancer Patients Treated by Radiotherapy | RECRUITING | NCT07332000 |
| aglatimagene besadenovec + valacyclovir | BIOLOGICAL | Phase PHASE2 | Prostate Cancer Patients Treated by Radiotherapy | RECRUITING | NCT07332000 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Stereotactic biopsy | PROCEDURE | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| rQNestin | DRUG | Phase PHASE1 | Malignant Glioma of Brain | ACTIVE_NOT_RECRUITING | NCT03152318 |
| CAN-2409 + valacyclovir | BIOLOGICAL | Phase PHASE1 | Lung Cancer | COMPLETED | NCT03131037 |
| placebo | BIOLOGICAL | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| aglatimagene besadenovec | BIOLOGICAL | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| Surgery | PROCEDURE | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Stereotactic body radiation therapy | RADIATION | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Chemoradiation | RADIATION | Phase PHASE2 | Borderline Resectable Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT02446093 |
| Aglatimagene besadenovec | BIOLOGICAL | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04495153 |
| AdV-tk + valacyclovir | BIOLOGICAL | Phase PHASE1 | Malignant Pleural Effusion | COMPLETED | NCT01997190 |
| Placebo + valacyclovir | BIOLOGICAL | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT01436968 |
| Aglatimagene besadenovec + valacyclovir | BIOLOGICAL | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT01436968 |
| Radiation | RADIATION | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| valacyclovir | DRUG | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02768363 |
| AdV-tk | BIOLOGICAL | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Radiation therapy | RADIATION | Phase PHASE2 | Malignant Glioma | COMPLETED | NCT00589875 |
| Temozolomide | DRUG | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| Valacyclovir | DRUG | Phase PHASE1 | Glioma, Malignant | COMPLETED | NCT03576612 |
| CAN-2409 | BIOLOGICAL | Phase PHASE2 | Malignant Glioma | COMPLETED | NCT00589875 |
Total products: 132